Critical limb ischemia update and the evolving role of drug-elution technologies

References

• Shishehbor MH, White CJ, Gray BH, et al. Critical limb ischemia: an expert statement. J Am Coll Cardiol. 2016;68:2002–2015.
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–1340.
   PubMed Web of Science ®Google Scholar
• Nehler MR, Duval S, Diao L, et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg. 2014;60(686–95):e2.
   Google Scholar
• Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing committee to develop guidelines for the management of patients with peripheral arterial disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463–e654.
   PubMed Web of Science ®Google Scholar
• Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5–S67.
   PubMed Web of Science ®Google Scholar
• Soga Y, Iida O, Takahara M, et al. Two-year life expectancy in patients with critical limb ischemia. JACC Cardiovasc Interv. 2014;7:1444–1449.
   PubMed Web of Science ®Google Scholar
• Iida O, Nakamura M, Yamauchi Y, et al. 3-year outcomes of the OLIVE registry, a prospective multicenter study of patients with critical limb ischemia: a prospective, multi-center, three-year follow-up study on endovascular treatment for infra-inguinal vessel in patients with critical limb ischemia. JACC Cardiovasc Interv. 2015;8:1493–1502.
   PubMed Web of Science ®Google Scholar
• Jones WS, Patel MR, Dai D, et al. Temporal trends and geographic variation of lower-extremity amputation in patients with peripheral artery disease: results from U.S. Medicare 2000-2008. J Am Coll Cardiol. 2012;60:2230–2236.
   PubMed Web of Science ®Google Scholar
• Goodney PP, Beck AW, Nagle J, et al. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009;50:54–60.
   PubMed Web of Science ®Google Scholar
• Barshes NR, Chambers JD, Cohen J, et al. Model to optimize healthcare value in ischemic Extremities 1 study C. Cost-effectiveness in the contemporary management of critical limb ischemia with tissue loss. J Vasc Surg. 2012;56(1015–1024):e1.
   PubMedGoogle Scholar
• Goodney PP, Tarulli M, Faerber AE, et al. Fifteen-year trends in lower limb amputation, revascularization, and preventive measures among medicare patients. JAMA Surg. 2015;150:84–86.
   PubMed Web of Science ®Google Scholar
• Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925–1934.
   PubMed Web of Science ®Google Scholar
• Menard MT, Farber A, Assmann SF, et al. Design and rationale of the best endovascular versus best surgical therapy for patients with critical limb ischemia (BEST-CLI) trial. J Am Heart Assoc. 2016;5(7).  pii: e003219. doi: 10.1161/JAHA.116.003219.
   Web of Science ®Google Scholar
• Popplewell MA, Davies H, Jarrett H, et al. Bypass versus angio plasty in severe ischaemia of the leg - 2 (BASIL-2) trial: study protocol for a randomised controlled trial. Trials. 2016;17:11.
   PubMedGoogle Scholar
• Malyar NM, Reinecke H, Freisinger E. Restenosis after endovascular revascularization in peripheral artery disease. Vasa. 2015;44:257–270.
   PubMed Web of Science ®Google Scholar
• Hawkins BM. Ultrasound plus paclitaxel trumps drug-coated balloon: progress in the periphery? JACC Cardiovasc Interv. 2016;9:2154–2156.
   PubMed Web of Science ®Google Scholar
• Thukkani AK, Kinlay S. Endovascular intervention for peripheral artery disease. Circ Res. 2015;116:1599–1613.
   PubMed Web of Science ®Google Scholar
• Muradin GS, Bosch JL, Stijnen T, et al. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology. 2001;221:137–145.
   PubMed Web of Science ®Google Scholar
• Romiti M, Albers M, Brochado-Neto FC, et al. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47:975–981.
   PubMed Web of Science ®Google Scholar
• Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331–338.
   PubMed Web of Science ®Google Scholar
• Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–699.
   PubMed Web of Science ®Google Scholar
• Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries - Paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–1365.
   PubMed Web of Science ®Google Scholar
• Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504.
   PubMed Web of Science ®Google Scholar
• Lammer J, Bosiers M, Zeller T, et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011;54:394–401.
   PubMed Web of Science ®Google Scholar
• Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty evidence from the randomized PACIFIER trial. Circ-Cardiovasc Inte. 2012;5:831–840.
   PubMed Web of Science ®Google Scholar
• Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013;6:1295–1302.
   PubMed Web of Science ®Google Scholar
• Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. Jacc-Cardiovasc Inte. 2013;6:274–281.
   PubMed Web of Science ®Google Scholar
• Rosenfield K, Jaff MR, White CJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153.
   PubMed Web of Science ®Google Scholar
• Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502.
   PubMed Web of Science ®Google Scholar
• Rastan A, Tepe G, Krankenberg H, et al. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J. 2011;32:2274–2281.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Piorkowski M, Werner M, et al. First experience with drug-eluting balloons in infrapopliteal arteries restenosis rate and clinical outcome. J Am Coll Cardiol. 2011;58:1105–1109.
   PubMed Web of Science ®Google Scholar
• Bosiers M, Scheinert D, Peeters P, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012;55:390–399.
   PubMed Web of Science ®Google Scholar
• Scheinert D, Katsanos K, Zeller T, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease. J Am Coll Cardiol. 2012;60:2290–2295.
   PubMed Web of Science ®Google Scholar
• Liistro F, Porto I, Angioli P, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128:615–621.
   PubMed Web of Science ®Google Scholar
• Siablis D, Kitrou PM, Spiliopoulos S, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease the IDEAS randomized controlled trial. JACC-Cardiovasc Inte. 2014;7:1048–1056.
   PubMed Web of Science ®Google Scholar
• Zeller T, Baumgartner I, Scheinert D, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64:1568–1576.
   PubMed Web of Science ®Google Scholar
• Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–710.
   PubMed Web of Science ®Google Scholar
• Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the zilver PTX randomized trial. Circulation. 2016;133:1472–1483. discussion 1483.
   PubMed Web of Science ®Google Scholar
• Tepe G, Schnorr B, Albrecht T, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons 5-year follow-up of the THUNDER trial. JACC-Cardiovasc Inte. 2015;8:102–108.
   PubMed Web of Science ®Google Scholar
• Katsanos K, Spiliopoulos S, Karunanithy N, et al. Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery. J Vasc Surg. 2014;59(1123–1133):e8.
   PubMedGoogle Scholar
• Gandini R, Del Giudice C. Local ultrasound to enhance paclitaxel delivery after femoral-popliteal treatment in critical limb ischemia the PACUS trial. Jacc-Cardiovasc Inte. 2016;9:2147–2153.
   PubMed Web of Science ®Google Scholar
• Rastan A, Brechtel K, Krankenberg H, et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents long-term results from a randomized trial. J Am Coll Cardiol. 2012;60:587–591.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Ulrich M, Winkler B, et al. Angiographic patency and clinical outcome after balloon-angioplasty for extensive infrapopliteal arterial disease. Catheter Cardio Inte. 2010;76:1047–1054.
   PubMed Web of Science ®Google Scholar
• Katsanos K, Kitrou P, Spiliopoulos S, et al. Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and Bayesian Network meta-analysis of randomized controlled trials. J Endovasc Ther. 2016;23:851–863.
   PubMed Web of Science ®Google Scholar
• Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–1888.
   PubMed Web of Science ®Google Scholar